22.09
-2.00%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Zhejiang Wolwo Bio-Pharmaceutical Co
Its shares trade on Shenzhen under the ticker 300357.SZ. It has been listed since 21 January 2014. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.06bn and net income of CN¥380.9m. At that date it held total assets of CN¥2.90bn and shareholders' equity of CN¥2.62bn.
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. engages in the research and development, manufacture, and sale of biopharmaceutical products. The company is headquartered in Huzhou, Zhejiang. The company went IPO on 2014-01-21. The firm's main products include Dermatophagoides Farinae Drops and Dermatophagoides Farinae Skin Prick Diagnostic Kits. The firm's products are primarily used for the treatment of allergic rhinitis caused by dust mite allergy, the desensitization of allergic asthma and the in-vivo diagnosis of dust mite drops. The firm distributes its products in domestic market.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 21 Jan 2014
- Employees
- 1,608
- Website
- wolwobiotech.com ↗
Leadership
Pay as last reported
- Mr. Gengxi HuChairman of the Board, since 2011CN¥780,000
- Mr. Guoqi WangFinance DirectorCN¥1.0m
- Mr. Jianming HeGeneral ManagerCN¥660,000
- Mr. Zhenwei GuanDeputy General Manager, Secretary of the BoardCN¥650,000
- Mr. Ziqiang BiDeputy General Manager, Director, since 2016CN¥780,000
- Ms. Lu ZhangDeputy General Manager, Director, since 2011CN¥780,000
- Ms. Mushuang HuDeputy General Manager
- Ms. Yanni ChenDirector
- Mr. Guoliang XuIndependent DirectorCN¥120,000
- Mr. Feida ZhangIndependent DirectorCN¥120,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 46
- Environment
- 65
- Social
- 39
- Governance
- 34
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Zhejiang Wolwo Bio-Pharmaceutical Co Ltd has 1,608 employees focused on biopharmaceutical R&D and manufacturing.
- Dermatophagoides Farinae Drops are a key product for treating dust mite allergy-related allergic rhinitis.
- The company's domestic market distribution strategy supports its primary product sales in China.
Weaknesses
- The company's products are limited to dust mite allergy treatments without broader therapeutic applications.
- Zhejiang Wolwo's reliance on domestic market distribution restricts international expansion opportunities.
- The firm's focus on a single allergy treatment segment may limit market diversification.
Opportunities
- Expanding into international markets could leverage the growing global demand for allergy treatments.
- Developing new biopharmaceutical products could diversify the company's portfolio beyond dust mite allergies.
- Increasing R&D investment may lead to innovative treatments for other allergic conditions.
Threats
- Competition from other pharmaceutical companies in the Health Care sector could impact market share.
- Regulatory changes in China's pharmaceutical industry might affect product approvals.
- Economic downturns could reduce consumer spending on allergy treatments in the domestic market.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.